期刊
BIOMEDICINES
卷 11, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines11051296
关键词
CD16; glycosylphosphatidylinositol-anchored 80 kD protein; immune checkpoint inhibition; latency-associated peptide-1; myeloid-derived suppressor cells; renal cell carcinoma
The combination of immune checkpoint inhibition (ICI) therapy with other treatments can improve therapeutic outcomes. In this study, the expression of various myeloid-derived suppressor cells (MDSCs) markers, such as GPI-80, CD16, and LAP-1, were analyzed before and during ICI therapy in 51 patients with advanced renal cell carcinoma. It was found that elevated CD16 and LAP-1 expressions after treatment were associated with a poor response to ICI therapy, while higher GPI-80 expression in neutrophils before therapy was correlated with a complete response.
The therapeutic outcome of immune checkpoint inhibition (ICI) can be improved through combination treatments with ICI therapy. Myeloid-derived suppressor cells (MDSCs) strongly suppress tumor immunity. MDSCs are a heterogeneous cell population, originating from the unusual differentiation of neutrophils/monocytes induced by environmental factors such as inflammation. The myeloid cell population consists of an indistinguishable mixture of various types of MDSCs and activated neutrophils/monocytes. In this study, we investigated whether the clinical outcomes of ICI therapy could be predicted by estimating the status of the myeloid cells, including MDSCs. Several MDSC indexes, such as glycosylphosphatidylinositol-anchored 80 kD protein (GPI-80), CD16, and latency-associated peptide-1 (LAP-1; transforming growth factor- fi1 precursor), were analyzed via flow cytometry using peripheral blood derived from patients with advanced renal cell carcinoma (n = 51) immediately before and during the therapy. Elevated CD16 and LAP-1 expressions after the first treatment were associated with a poor response to ICI therapy. Immediately before ICI therapy, GPI-80 expression in neutrophils was significantly higher in patients with a complete response than in those with disease progression. This is the first study to demonstrate a relationship between the status of the myeloid cells during the initial phase of ICI therapy and clinical outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据